Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mecarbinate SCHEMBL29380431 | 0.85 | LMNA (0.72) | ALOX5MEN1KMT2AALOX15GAA | |
| Mecarbinate SCHEMBL2109102 | 0.85 | LMNA (0.72) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL28726995 | 0.83 | ALOX5 (0.61) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL28259795 | 0.81 | ALOX5 (1.00) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL28726996 | 0.81 | ALOX5 (0.60) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL25943143 | 0.79 | ALOX5 (0.56) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL9095202 | 0.77 | ALOX5 (0.53) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL27608072 | 0.77 | GAA (0.58) | ALOX5MEN1KMT2AALOX15GAA | |
| SCHEMBL25941571 | 0.74 | SMN1; SMN2 (0.54) | ALOX5MEN1KMT2AALOX15LMNA | |
| Hydrochloric Acid SCHEMBL31397817 | 0.74 | KDM4E (0.64) | ALOX5MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812228-B2 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE MOVEMENT DISORDERS CHARACTERIZED BY HYPOKINESIA, TREMOR, AND MUSCULAR RIGIDITY | WARNER-LAMBERT COMPANY | 2004-11-02 | — | — | US | disclosed |
| EP-1282625-B1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER LAMBERT CO (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030220335-A1 | Benzoxazines for use in the treatment of parkinson's disease | WARNER-LAMBERT COMPANY | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220335-A1 | Benzoxazines for use in the treatment of parkinson's disease | PARK7, HAX1, SNCA | ALOX5 710/4885MEN1 4615/4885KMT2A 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.